A meta‐analysis of existing RCTs suggests that SGLT2 inhibitors may indeed be associated with a lower risk of incident AF (odds ratio 0.82 [95% CI 0.72‐0.93]; P = 0.002), consistent with our study.23 Here, SLC5A2 is linked to atrial fibrillation.